New cocktail of drugs takes on tough lung cancers in Never-Smokers
NCT ID NCT03786692
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to a standard three-drug chemotherapy regimen (carboplatin, pemetrexed, and bevacizumab) helps people with advanced non-squamous lung cancer live longer without their disease worsening. The study enrolls 107 patients whose tumors either have a specific EGFR mutation or who have never smoked and lack certain other mutations. Researchers are comparing the combination with and without atezolizumab to see if the immune-boosting agent improves outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin, pemetrexed, bevacizumab, and atezolizumab (drug combination)
What this could lead to
If it works, this could point toward a more effective first-line treatment for certain advanced lung cancers, potentially improving how long patients live without their disease getting worse.
What could go wrong
This is a mid-stage trial with only 107 participants, so results may not apply to everyone. Adding immunotherapy to chemotherapy also raises the risk of immune-related side effects, and the benefit over standard treatment is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA OF LUNG, TNM STAGE 4 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States